Skip to content

RCT of Gastric ESD With or Without Epineprhine Added Solution

Multicenter Randomized Controlled Trial of Gastric Endoscopic Submucosal Dissection With or Without Epineprhine Added Solution

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04032119
Enrollment
800
Registered
2019-07-25
Start date
2020-01-10
Completion date
2023-01-31
Last updated
2025-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastric Cancer, Gastric Neoplasm

Keywords

Gastric Endoscopic submucosal dissection, Epinephrine

Brief summary

This is an international multi-center randomised controlled study comparing outcomes of gastric endoscopic submucosal dissection (ESD) with or without addition of epinephrine in the submucosal injection solution.

Detailed description

Endoscopic submucosal dissection (ESD) is an endoscopic technique aiming to achieve en-bloc resection of mucosal neoplastic lesion in the gastrointestinal tract. It is now considered as the standard of treatment for early gastric cancer confined to the mucosa, achieving an excellent overall survival comparable to that of surgical resection. Important adverse events associated with gastric ESD include hemorrhage (intraoperative or delayed) and perforation. The reported incidence of intraprocedural and delayed hemorrhage of gastric ESD is generally higher than that of esophageal or colorectal ESD5. This is likely due to the rich blood supply of the stomach penetrating from the muscularis to the submucosal layer. Bleeding during ESD would result in difficulty in visualizing the correct plane of dissection from blood clots obscuring view of the endoscope. As a result, prolonged procedural time may be required to achieve hemostasis and obtain adequate view for dissection. There are currently different options of the solution for submucosal injection during gastric ESD. Epineprhine has often been added into these solutions with the aim of causing vasoconstrictive effect and potentially reduce bleeding during the procedure. The use of epinephrine has been recommended when removing larger pedunculated polyps with endoscopic mucosal resection (EMR)6. However the exact clinical benefit of adding epinephrine during gastric ESD has not been proven in the literature. On the other hand, when larger dose of epinephrine is absorbed systemically it may rarely cause significant tachycardia and generalized vasoconstriction, putting patients at risk of myocardial infarction or cerebrovascular accident. A retrospective propensity score analysis was previously performed in one of our Japanese center (Presented at JGCA 2019, Shizuoka). After adjustment of important confounding factors including age, sex, tumor location, specimen size, depth of tumor invasion, presence of histological ulcer or scar and operators' experience, the addition of epinephrine into submucosal solution was associated with a significantly shorter procedural time upon multivariate analysis. The mean procedural time was 72±54 minutes versus 93±62 minutes with and without epinephrine respectively. (p\<0.001) With the encouraging result from a single center retrospective study, we plan to conduct a prospective multicenter randomized controlled study to confirm the benefit of adding epinephrine into the submucosal solution during gastric ESD.

Interventions

PROCEDUREEndoscopic submucosal dissection

Endoscopic submucosal dissection

DRUGEpinephrine

Epinephrine

Sponsors

Osaka International Cancer Institute
CollaboratorUNKNOWN
Fukuoka University
CollaboratorOTHER
Changi General Hospital
CollaboratorOTHER
Kyoto 2nd Red Cross Hospital
CollaboratorUNKNOWN
Ishikawa Prefectural Central Hospital
CollaboratorUNKNOWN
Kosin University Gospel Hospital
CollaboratorOTHER
Machida General Hospital
CollaboratorUNKNOWN
Nara City Hospital
CollaboratorUNKNOWN
Wakayama Red Cross Hospital
CollaboratorUNKNOWN
JCHO Osaka Hospital
CollaboratorUNKNOWN
Sapporo Kinentou hospital
CollaboratorUNKNOWN
Japan Community Healthcare Organization Osaka Hospital
CollaboratorUNKNOWN
Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Selection criteria: Presence of intramucosal neoplastic lesions in the stomach planning for endoscopic submucosal dissection (Vienna Classification Category 3 and 4 lesion) * Target subjects receiving sufficient briefing from the attending physician regarding the content of this study and providing informed consent for participation

Exclusion criteria

* Recurrent / remnant lesion after previous endoscopic resection * Lesions arising from surgical anastomotic site, such as gastrojejunostomy / gastroduodenostomy. * Marked electrolyte abnormalities * Hemostatic or coagulative abnormalities * Patient on anti-coagulant agents, including warfarin and other direct oral anti-coagulants (those on antiplatelet can be included) * Failure of vital organ (heart, lungs, liver, or kidneys) function * Allergic to components of injection solutions: Epinephrine, hyaluronic acid etc * Other cases deemed by the examining physician as unsuitable for safe treatment

Design outcomes

Primary

MeasureTime frameDescription
Overall procedural timeDuring the endoscopic procedureFrom the beginning of mucosal incision till the end of submucosal dissection, excluding time for prophylactic homeostasis

Secondary

MeasureTime frameDescription
Maximum systolic blood pressureDuring the endoscopic procedureMaximum systolic blood pressure during ESD
Maximum heart rateDuring the endoscopic procedureMaximum heart rate during ESD
Adverse event - Delayed hemorrhage30 daysDelayed hemorrhage (Based on CTCAE definition)
Adverse event - Perforation30 daysPerforation (Based on CTCAE definition)
Adverse event - Cardiovascular event30 daysCardiovascular event (Based on CTCAE definition)
Adverse event - Cerebrovascular event30 daysCerebrovascular event (Based on CTCAE definition)
Other adverse event30 daysBased on CTCAE definition
Number of intra-procedural hemorrhage eventsDuring the endoscopic procedureThe number of oozing or spurting bleeding events during a procedure, requiring hemostasis with coagulating forceps
Size of lesionDuring the endoscopic procedureSize of lesion
Depth of invasionDuring the endoscopic procedureDepth of tumor invasion
Vertical marginDuring the endoscopic procedureVertical margin involvement
Horizontal marginDuring the endoscopic procedureHorizontal margin involvement
DifferentiationDuring the endoscopic procedureDegree of differentiation for cancer of stomach
Lymphovascular invasionDuring the endoscopic procedureLymphovascular invasion on pathology
PathologyDuring the endoscopic procedureFinal histology based on Vienna Classification

Countries

Hong Kong, Japan, Singapore, South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026